Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 204 of 5804
-
New drug cocktail aims to shrink recurrent ovarian tumors
Disease control Not yet recruitingThis is an open-label, multicenter Phase II clinical study conducted in subjects with recurrent ovarian cancer.
Phase: PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug hopes to ease rare lung condition in children
Disease control Not yet recruitingThe goal of this study is to learn about the safety of sotatercept and how well Japanese children tolerate it, when taken along with standard (usual) pulmonary arterial hypertension (PAH) treatment. Researchers also want to learn what happens to it in a person's body over time an…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for NMOSD patients: drug aims to slash relapse rate
Disease control Not yet recruitingThe primary objective of this study is to confirm the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of ravulizumab in the treatment of Chinese adults with anti-aquaporin-4 (AQP4) antibody (Ab) + neuromyelitis optica spectrum disorder (NMOSD).
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a simple ultrasound improve rattlesnake bite care?
Diagnosis Not yet recruitingEarly identification of tissue injury from a rattlesnake bite is critical to prevent complications and reduce health care costs. Given the limitations of clinical assessment, there is a need to develop a more objective reproducible, anatomically detailed diagnostic tool for to ac…
Sponsor: University of Arizona • Aim: Diagnosis
Last updated Jul 19, 2026 00:00 UTC
-
Two-Drug cocktail aims to shrink Hard-to-Treat esophageal and stomach tumors
Disease control Not yet recruitingThis is a single-arm, multi-center phase II study to evaluate the efficacy and safety of sacituzumab tirumotecan (Sac-TMT/SKB264) combined with tagitanlimab (KL-A167) as 2nd line therapy for recurrent or metastatic esophageal squamous cell carcinoma (ESCC) or gastric/gastroesopha…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New combo therapy aims to fight aggressive brain tumors in kids
Disease control TerminatedThis is a multisite, phase I/II clinical trial in children and young adults with newly-diagnosed high-grade glioma (HGG), diffuse midline glioma (DMG) and recurrent HGG/DMG, Medulloblastoma (MB), or ependymoma (EPN) to determine the safety, immunogenicity, and efficacy of a CMV-d…
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Experimental drug combo aims to make inoperable stomach cancers removable
Disease control Not yet recruitingThis is a prospective, single-arm, exploratory clinical study designed to evaluate the efficacy and safety of retlirafusp alfa plus CAPOX as conversion therapy in patients with potentially resectable gastric or gastroesophageal junction adenocarcinoma. Eligible participants will …
Phase: PHASE2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Zimbabwe study targets cancer prevention with vaccines and mental health care
Prevention Not yet recruitingAim: The main goal of this observational study is to determine the prevalence of Human Papilloma Virus(HPV) infection, and Hepatitis B (Hep B) immunity amongst women of childbearing age 13 to 45 years) attending clinics at Mtshabezi Mission and Matobo clinic respectively; and ass…
Phase: PHASE4 • Sponsor: Eunice Dube • Aim: Prevention
Last updated Jun 27, 2026 08:12 UTC
-
New drug combo aims to keep lung cancer in check longer
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.
Phase: PHASE2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug combo aims to boost surgery success in colon cancer
Disease control Not yet recruitingThis is a Phase II, single-arm, open-label trial evaluating the feasibility, safety, and preliminary activity of neoadjuvant Zanzalintinib (a VEGFR-targeting TKI) and Retifanlimab (an anti-PD-1 antibody) in patients with resectable stage II-III mismatch repair-proficient (pMMR) c…
Phase: PHASE2 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of GKL-006Allo Injection in participants with advanced solid tumors.
Phase: PHASE1 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New pill aims to halt lung scarring in thousands
Disease control Not yet recruitingThis study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they have been diagnosed with this condition within the last 3 years and are at risk of developing progressive pulmonary fibros…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Leukemia combo shot and pill shows promise in early trial
Disease control Not yet recruitingTo find out if giving blinatumomab as injections under the skin and olverembatinib can help to control the disease in patients with Ph-positive ALL.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New trial hunts down lingering melanoma DNA to stop cancer return
Disease control Recruiting nowClear-Me is a biomarker-driven phase II study that tests whether the combination anti- lymphocyte-activation gene-3 (LAG3)/anti-programmed cell death protein 1(PD-1) inhibition Bristol-Myers Squibb (BMS986213) is superior to anti-PD-1 inhibition in patients with detectable circul…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug trial aims to protect Kids' kidneys from IgA nephropathy
Disease control Recruiting nowA Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to \<18 years with primary immunoglobulin A nephropathy (IgAN).
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New hope for tough myeloma: Two-Drug combo takes on relapsed cancer
Disease control Not yet recruitingThis phase II trial compares the effect of the combination of daratumumab-hyaluronidase (daratumumab) and teclistamab to the usual treatment of daratumumab, pomalidomide, dexamethasone or daratumumab, carfilzomib and dexamethasone in treating patients with multiple myeloma that h…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug aims to ease anemia in bone marrow cancer patients
Disease control Recruiting nowThe main aim of this study is to find out how well elritercept works to improve anemia in participants with myelofibrosis (MF) who are taking ruxolitinib when compared to placebo. Other aims are to learn how elritercept improves anemia compared to placebo; to learn if elritercep…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New foam could tame stubborn scalp and face rash
Disease control Not yet recruitingThis study will assess the safety and efficacy of Roflumilast foam 0.3% (ZORYVE®) versus vehicle applied once a day for 8 weeks by trial participants with seborrheic dermatitis.
Phase: PHASE3 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Sound waves open brain barrier to deliver cancer drug in kids
Disease control Not yet recruitingThis is an open-label phase 1 safety and feasibility study evaluating a novel combination therapy for progressive and relapsed diffuse midline glioma (DMG) and other progressive and relapsed high-grade brain tumors. This study combines intravenous nivolumab therapy infused follow…
Phase: PHASE1 • Sponsor: Children's National Research Institute • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New biologic MK-1045 targets Hard-to-Treat blood cancers
Disease control Not yet recruitingResearchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These are blood cancers that affect B-cells in the blood, bone marrow, or lymph nodes. The g…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC